1. Home
  2. SCYX vs USEG Comparison

SCYX vs USEG Comparison

Compare SCYX & USEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • USEG
  • Stock Information
  • Founded
  • SCYX 1999
  • USEG 1966
  • Country
  • SCYX United States
  • USEG United States
  • Employees
  • SCYX N/A
  • USEG N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • USEG Oil & Gas Production
  • Sector
  • SCYX Health Care
  • USEG Energy
  • Exchange
  • SCYX Nasdaq
  • USEG Nasdaq
  • Market Cap
  • SCYX 36.8M
  • USEG 42.2M
  • IPO Year
  • SCYX 2014
  • USEG N/A
  • Fundamental
  • Price
  • SCYX $0.74
  • USEG $1.58
  • Analyst Decision
  • SCYX
  • USEG Strong Buy
  • Analyst Count
  • SCYX 0
  • USEG 1
  • Target Price
  • SCYX N/A
  • USEG $3.50
  • AVG Volume (30 Days)
  • SCYX 170.9K
  • USEG 9.2M
  • Earning Date
  • SCYX 08-07-2025
  • USEG 08-06-2025
  • Dividend Yield
  • SCYX N/A
  • USEG N/A
  • EPS Growth
  • SCYX N/A
  • USEG N/A
  • EPS
  • SCYX N/A
  • USEG N/A
  • Revenue
  • SCYX $2,630,000.00
  • USEG $16,340,000.00
  • Revenue This Year
  • SCYX $463.61
  • USEG $23.82
  • Revenue Next Year
  • SCYX $310.80
  • USEG N/A
  • P/E Ratio
  • SCYX N/A
  • USEG N/A
  • Revenue Growth
  • SCYX N/A
  • USEG N/A
  • 52 Week Low
  • SCYX $0.72
  • USEG $0.81
  • 52 Week High
  • SCYX $2.29
  • USEG $6.40
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 37.94
  • USEG 51.25
  • Support Level
  • SCYX $0.72
  • USEG $1.44
  • Resistance Level
  • SCYX $0.85
  • USEG $1.69
  • Average True Range (ATR)
  • SCYX 0.05
  • USEG 0.29
  • MACD
  • SCYX -0.01
  • USEG -0.02
  • Stochastic Oscillator
  • SCYX 9.61
  • USEG 21.19

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About USEG U.S. Energy Corp. (DE)

US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.

Share on Social Networks: